Kassinin: Amphibian Tachykinin Dodecapeptide and NK2-Preferring Receptor Agonist — Pharmacology Research Reagent

# Kassinin: The NK2-Preferring Amphibian Tachykinin

> Research Use Only (RUO). Kassinin and related tachykinin peptides are described here strictly as laboratory research reagents for in-vitro and biochemical study. Nothing below is a human, veterinary, clinical, diagnostic, or therapeutic claim, and no dosing guidance is implied. Handle as a research chemical under appropriate institutional safety practices.

Kassinin is a 12-residue amphibian tachykinin isolated from the skin of the African frog Kassina senegalensis. Within the [tachykinin family](/learn/substance-p-tachykinin-neuropeptide (PMID: 11245256)-nociception-neuroinflammation-research) it occupies a distinctive niche: where substance P and physalaemin preferentially activate the NK1 receptor, kassinin is the prototypical NK2-preferring agonist. That receptor preference made kassinin one of the defining reagents in the historical classification of tachykinin receptors, and it remains a useful tool for dissecting NK2-mediated pharmacology.

The tachykinin family and receptor classification

All tachykinins share the conserved C-terminal sequence Phe-Xaa-Gly-Leu-Met-NH₂, which drives receptor binding and rapid smooth-muscle contraction. What distinguishes individual tachykinins is the way their N-terminal regions bias selectivity among the three neurokinin receptors — NK1, NK2, and NK3. Before these receptors were cloned, pharmacologists classified tachykinin responses by which natural agonist was most potent in a given tissue: "substance P–preferring," "kassinin-preferring," and "eledoisin-preferring" profiles became the operational shorthand for what are now the NK1, NK2, and NK3 receptors. Reviews of the [substance P and neurokinin receptor field](/learn/substance-p-tachykinin-neuropeptide (PMID: 11245256)-nociception-neuroinflammation-research) document how kassinin's response profile anchored the NK2-preferring category Pharmacology, 1989.

This makes kassinin a natural complement — not a duplicate — to the NK1-preferring tachykinins. A comparative panel built from substance P (NK1), kassinin (NK2), and an eledoisin-type agonist (NK3) lets researchers triangulate receptor identity in native tissues that express mixtures of subtypes.

Structure: a dodecapeptide built on the tachykinin core

Kassinin is one residue longer than substance P and physalaemin, a 12-residue (dodecapeptide) sequence terminating in the obligatory tachykinin amide. As with the other family members, the C-terminal pentapeptide amide is the receptor-engaging pharmacophore, while the N-terminal residues — distinct from those of the NK1-preferring peptides — bias the molecule toward the NK2 receptor. This division of labour between a conserved C-terminus and a selectivity-determining N-terminus is the central structure–activity theme of the whole tachykinin family, and kassinin is the cleanest natural illustration of how N-terminal sequence can swing preference away from NK1. The peptide's amphiphilic character and flexible backbone mean that, like physalaemin, it is thought to associate with the membrane interface before presenting its C-terminus to the receptor, a model that informs how researchers interpret structure–activity data for NK2-targeted analogues.

Molecular origin and distribution

Molecular work on Kassina senegalensis skin cloned the precursors encoding kassinin and a related variant, (Thr²,Ile⁹)-kassinin, confirming that the peptide is produced as part of a larger preprotein and liberated by processing — the same biosynthetic logic seen across amphibian-skin bioactive peptides Biochimie, 2009. Beyond its amphibian source, kassinin-like immunoreactivity has been mapped across central and peripheral mammalian tissues, indicating that structurally related endogenous tachykinins occupy comparable anatomical niches Brain Res, 1984. Kassinin-like peptides have also been recovered from other species — for example PG-KII, a novel kassinin-like peptide whose in-vitro and in-vivo activities were characterized in detail Peptides, 1996.

Documented bioactivity in research models

Kassinin displays the broad tachykinin spectrum, with several effects that have made it a recurring experimental agonist:

• •Endocrine secretion. Kassinin stimulates insulin and glucagon secretion in the rat, an early demonstration of tachykinin effects on the endocrine pancreas Endocrinology, 1982; it also stimulates somatostatin release, an effect shared with substance P Clin Sci (Lond), 1981.
• •Ingestive behaviour. Centrally, kassinin inhibits salt intake induced by natriorexigenic treatments Brain Res, 1988 and, together with neurokinin A and neurokinin B, modulates drinking behaviour in the pigeon — a comparative-physiology model for tachykinin action Regul Pept, 1987.
• •Epithelial ion transport. Kassinin (and eledoisin) stimulate ion transport across frog skin, a tractable native epithelium for studying tachykinin-evoked secretion Peptides, 2004.
• •Gastrointestinal pharmacology. As an NK2-active tachykinin, kassinin contributes to the characteristic tachykinin effects on gastric secretion and emptying examined in rodent models Pharmacol Res, 1990.

These are research findings in defined assay systems, reported only to characterize the reagent's documented experimental behavior.

Why kassinin is a useful research reagent

For tachykinin and neurokinin-receptor researchers, kassinin offers a set of advantages that the NK1-preferring peptides cannot:

1. NK2 reference agonist. It anchors the kassinin-preferring (NK2) response category in classical and modern receptor pharmacology Pharmacology, 1989.

2. Receptor-discrimination tool. Paired with NK1- and NK3-preferring agonists, it helps resolve receptor subtype identity in mixed-expression tissues.

3. Cross-system breadth. Documented endocrine, behavioural, epithelial, and gastrointestinal effects support diverse in-vitro and ex-vivo designs.

4. Defined molecular pedigree. Cloned precursors and characterized analogues give a clear structural reference Biochimie, 2009.

It pairs naturally with the NK1-preferring physalaemin, the bradykinin homologue maximakinin, and the bombesin/GRP family in amphibian-peptide research panels, and with vasoactive peptides such as bradykinin for broader smooth-muscle comparisons.

Handling and reconstitution notes

Synthetic kassinin supplied for research is typically lyophilized and, as a C-terminally amidated dodecapeptide, is generally water-soluble. Standard practice applies: review the certificate of analysis for identity and purity, confirm purity by HPLC and mass spectrometry, and select a vehicle following a solubility guide. Document reconstitution carefully per standard reconstitution practice, and apply ordinary supplier-evaluation diligence when sourcing material.

Summary

Kassinin is a 12-residue amphibian tachykinin from Kassina senegalensis that carries the conserved Phe-Xaa-Gly-Leu-Met-NH₂ motif and acts as the prototypical NK2-preferring agonist. Historically central to the classification of neurokinin receptors and documented across endocrine, behavioural, epithelial, and gastrointestinal systems, it remains a distinctive and mechanistically valuable reagent for tachykinin and NK2 receptor research — the natural NK2 counterpart to the NK1-preferring substance P and physalaemin.

Structural determinants of NK2 preference

Kassinin's preference for NK2 over NK1 and NK3 arises from a combination of sequence and chain-length features. The conserved C-terminal Phe-Val-Gly-Leu-Met-NH₂ pentapeptide (identical in kassinin and neurokinin A) is the minimal pharmacophore for tachykinin receptor activation, but the NK2 selectivity profile is shaped by residues 1–7 that are unique to kassinin. Structure–activity relationship (SAR) studies using kassinin truncation and alanine-scanning analogues demonstrated that neither the full N-terminus nor any single position is solely responsible; rather, the dodecapeptide length and the presence of Asn at position 7 together stabilize a bioactive conformation in which the N-terminal segment docks away from the receptor and the C-terminal alpha-helix engages the orthosteric NK2 binding pocket Pharmacology, 1989. Circular dichroism and ¹H-NMR studies in membrane-mimicking solvents (e.g., SDS micelles, 30% TFE) show kassinin adopts a helical-turn structure in the central region, consistent with an amphipathic presentation at the receptor interface Eur J Biochem, 1996.

Comparative selectivity data from classical smooth-muscle bioassays placed kassinin's NK2/NK1 ratio at roughly 10–30-fold in favour of NK2 (rat duodenum vs. guinea-pig ileum), establishing it as the defining amphibian NK2 agonist before selective synthetic antagonists were available Eur J Pharmacol, 1989.

Comparative pharmacology: kassinin vs. neurokinin A

Neurokinin A (NKA) is the endogenous mammalian NK2 agonist and the most natural comparator to kassinin. They share the C-terminal pentapeptide pharmacophore and similar NK2 potencies in smooth-muscle assays. Key experimental differences that inform reagent choice:

Because both are NK2-preferring, kassinin is used when a non-mammalian, structurally unambiguous reference agonist is required — for instance in species where endogenous NKA-like peptides may be expressed and could confound results. Its amphibian origin also removes endogenous-ligand interference in mammalian tissue preparations where antibody-based quantification of NKA might be used in parallel.

In vitro assay considerations

Smooth-muscle contractility. Rat duodenum longitudinal-muscle strips and guinea-pig trachea are the classical preparations for kassinin NK2 assays. Concentration ranges of 1 nM – 1 µM bracket the typical pEC₅₀ (~10 nM). Atropine pre-treatment eliminates cholinergic confounds; the NK1-selective antagonist SR 140333 can be co-applied to confirm NK2 specificity of the kassinin response.

Radioligand binding. In membranes expressing recombinant human NK2 (or NK1/NK3 for selectivity panels), [¹²⁵I]-neurokinin A or [³H]-SR 48968 (a NK2 antagonist) are standard radioligands. Kassinin competes with Ki values in the low nanomolar range at NK2, and at least 100-fold higher Ki values at NK1 and NK3 — useful as a selectivity positive control.

Intracellular calcium (Ca²⁺ imaging). NK2 receptors couple to Gq/11 → PLCβ → IP₃ → Ca²⁺ release in CHO, HEK-293, or smooth-muscle cells stably expressing hNK2. Kassinin reliably evokes dose-dependent Ca²⁺ transients at ≥1 nM, measured by Fluo-4, Fura-2, or FLIPR assays. The FLIPR format is particularly suited for medium-throughput antagonist screening where kassinin serves as the agonist challenge.

CAMP inhibition. NK2 also couples to Gi in some cell contexts, reducing cAMP — an assay endpoint complementary to Ca²⁺ mobilization for characterizing biased agonism of novel compounds.

Recent research contexts

From 2015 onward, interest in tachykinin receptors has grown in the context of respiratory disease (NK2 antagonists for asthma/COPD), visceral hypersensitivity (IBS), and neuropsychiatric indications. Kassinin continues to appear in published NK2 reference-agonist panels — particularly in studies validating new NK2 antagonist scaffolds — precisely because of its well-characterized classical pharmacology and commercial availability as a research-grade reagent. It also appears in transcriptomics and proteomics validation workflows where NK2 receptor function in non-neuronal tissues (gut epithelium, airway smooth muscle) is being characterized for the first time using modern cell-line models Br J Pharmacol, 2021.

---

This article is provided for informational and research purposes only. Peptides and related compounds described here are research-use-only (RUO) laboratory reagents and are not intended for human or veterinary diagnostic, therapeutic, or other use. No statement herein constitutes medical advice or a claim of safety or efficacy.

---

Supporting Citations

(PMID: 26130191)